The relationship among proton pump inhibitors, bone disease and fracture
- 5 May 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 10 (6) , 901-912
Abstract
There is growing concern about a possible association between the use of proton pump inhibitors (PPIs) and the development of fragility fractures, most notably hip and vertebral fractures. As PPIs are widely used in clinical practice, this association is of paramount clinical importance. The authors review the published papers analyzing the relationship between PPI use and the occurrence of fragility fractures. The authors also explore the data supporting possible mechanisms through which PPIs may increase the risk of fracture, including the effects of PPIs on calcium homeostasis, bone mineral density and direct effects of PPIs on bone metabolism. Overall, though multiple observational studies have demonstrated an association between PPIs and fragility fractures, the lack of a proven mechanism through which PPIs increase the risk of fracture suggests that this association may not be causal. At this time, the authors do not recommend discontinuing PPIs in patients with a history of fracture or those at increased risk of fracture. However, clinicians should still endeavor to avoid using PPIs in situations where benefits are minimal or clinical indications are lacking.Keywords
This publication has 64 references indexed in Scilit:
- Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatmentOsteoporosis International, 2010
- Peak bone mass from longitudinal data: Implications for the prevalence, pathophysiology, and diagnosis of osteoporosisJournal of Bone and Mineral Research, 2010
- Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis StudyCanadian Medical Association Journal, 2009
- Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos)Osteoporosis International, 2005
- Health-related quality of life after osteoporotic fracturesOsteoporosis International, 2004
- Mortality and Locomotion 6 Months After Hospitalization for Hip FractureJAMA, 2001
- Oral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatology, 2000
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- Risk Factors for Hip Fracture in Men from Southern Europe: The MEDOS StudyOsteoporosis International, 1999
- Mortality Following Fractures in Older WomenArchives of internal medicine (1960), 1996